Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.

Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. Oral Oncol. 2019 10; 97:82-91.

View in: PubMed

subject areas

Aged
Antineoplastic Combined Chemotherapy Protocols
Disease-Free Survival
ErbB Receptors
Female
Head and Neck Neoplasms
Humans
Male
Methotrexate
Neoplasm Recurrence, Local
Quinazolines
Treatment Adherence and Compliance
Treatment Outcome

authors with profiles

Ezra Cohen